APYX:NSD-Apyx Medical Corporation (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 10.62

Change

-0.34 (-3.10)%

Market Cap

USD 0.40B

Volume

0.09M

Avg Analyst Target

USD 15.50 (+45.95%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Apyx Medical Corporation (APYX) Stock Analysis:
Based on the Apyx Medical Corporation stock forecasts from 1 analysts, the average analyst target price for Apyx Medical Corporation is USD 15.50 over the next 12 months. Apyx Medical Corporation’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Apyx Medical Corporation is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, Apyx Medical Corporation’s stock price was USD 10.62. Apyx Medical Corporation’s stock price has changed by -1.01% over the past week, -1.53% over the past month and +0.66% over the last year.

About

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and OEM. It offers electrosurgical generators based on its Helium Plasma ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-20 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

-0.59 (-0.14%)

USD43.36B 84.37 117.62
ALGN Align Technology Inc

-6.88 (-1.38%)

USD38.60B 52.77 48.05
PODD Insulet Corporation

-2.70 (-1.15%)

USD16.21B 2,208.27 199.97
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
ABMD Abiomed Inc

+0.73 (+0.24%)

USD13.74B 92.73 46.15
BRKR Bruker Corporation

-1.22 (-1.78%)

USD10.73B 39.93 25.78
TNDM Tandem Diabetes Care Inc

-0.14 (-0.11%)

USD7.90B 366.78 187.52
SWAV ShockWave Medical Inc

-4.05 (-2.80%)

USD5.90B N/A N/A
IART Integra LifeSciences Holdings ..

-0.36 (-0.54%)

USD5.77B 26.80 17.89
LIVN LivaNova PLC

-1.40 (-1.68%)

USD4.51B 77.40 N/A

ETFs Containing APYX

Symbol Name Weight Mer Price(Change) Market Cap
PQSG PGIM ETF Trust - PGIM QMA.. 0.00 % 0.29 %

N/A

USD0.01B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.16% 32% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.16% 32% F 23% F
Trailing 12 Months  
Capital Gain 0.66% 82% B- 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.66% 82% B- 58% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 30.30% 53% F 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.30% 53% F 76% C
Risk Return Profile  
Volatility (Standard Deviation) 64.18% 47% F 26% F
Risk Adjusted Return 47.21% 70% C- 66% D
Market Capitalization 0.40B 59% F 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 4.30 69% D+ 86% B
Price/Book Ratio 8.42 24% F 14% F
Price / Cash Flow Ratio -24.86 76% C 84% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -24.74% 51% F 38% F
Return on Invested Capital -18.62% 52% F 29% F
Return on Assets -12.93% 49% F 26% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.72 21% F 17% F
Short Percent 1.04% 82% B- 71% C-
Beta 0.87 66% D 66% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector